Flow-through Plasma circuit pathogen reduction device for patients with sepsis and/or liver failure

败血症是一种严重的血液微生物感染，是一种潜在的致命疾病。抗生素是治疗的主要手段，但不能科普压倒性的脓毒症，随着耐药细菌的发展，抗生素的有效性将逐渐降低。脓毒症也是肝衰竭患者死亡的主要原因之一。如今，随着抗生素耐药性的不断增加，迫切需要新的方法来对抗任何病因引起的脓毒症。用于重症监护病房的流通病原体减少模块（PRT）将是重症监护医学的重大突破。血浆微生物的有意义的减少将使传统的抗菌治疗再次有效，并将为世界各地的患者带来益处。该项目将满足这一需求。基于UCL开发的成熟，创新的概念，它将设计，制造，演示和测试（使用体外模型）人体规模的原型。这项工作将为合作伙伴产生新的可保护的知识产权，并使他们能够根据相关临床和商业利益相关者的意见，为商业级设备的开发和推出制定和降低商业计划。

Sepsis, overwhelming microbial infection of the bloodstream, is a potentially fatal condition. Antibiotics are the mainstay of treatment, but cannot cope with overwhelming sepsis, and as resistant bacteria develop, antibiotics will become progressively less effective. Sepsis is also one of the key reasons for patient demise in liver failure. Today, with ever increasing antibiotic resistance, new approaches are urgently required to combat sepsis from any aetiology. A flow-through pathogen reduction module (PRT) for use in intensive care units would be a major breakthrough for intensive care medicine. A meaningful reduction of plasma microbes would enable conventional antimicrobial treatments to be effective once more, and would deliver benefit to patients worldwide. The project will address this need. Building on a well-developed, innovative concept developed by UCL it will design, manufacture, demonstrate and test (using in vitro models) a human scale prototype. The work will generate new protectable IP for the partners, and enable them to develop and derisk business plans for the development and roll-out of a commercial grade device, building on input from relevant clinical and commercial stakeholders.